This reference antibody, modeled after inclacumab, is used in medical research and development to study the role of P-selectin (CD62p), a protein critical in inflammation and blood clotting, particularly in cardiovascular conditions such as acute myocardial infarction and thrombosis.

It inhibits the binding of leukocytes to vascular endothelial cells, a key step in vascular inflammation, and is developed as a targeted anti-inflammatory agent with potential to reduce myocardial damage following heart attacks.

Clinical trials have shown it reduces inflammation levels and improves blood flow in patients with acute coronary syndromes, positioning it as a promising biologic target for future treatments of coronary artery disease.